Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale
Authors:
Open Access
- 27 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 783181
Abstract
Background: Diuretic Resistance in Acute Heart Failure (DR-AHF) was designed to demonstrate the effectiveness of the early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in patients with AHF with renal dysfunction and to provide clinical evidence of loop diuretic resistance.Methods and Results: This single-centered, open-labeled, randomized, and controlled trial enrolled 128 patients hospitalized with AHF, as participants. These patients with a wet-warm phenotype, whose estimated glomerular filtration rates are of ≥15 ml/min/1.73 m2 and ≤ 60 ml/min/1.73 m2, with a cumulative urine output of <300 ml 2 h after the first dose of intravenous furosemide, will be randomly assigned 1:1 to receive standard care with an uptitrating intravenous furosemide alone, or a combination therapy with 15 mg of tolvaptan administered once daily for 2 days. The standard furosemide treatment will follow the latest position statements of the Heart Failure Association. The primary endpoint is the cumulative urine output at 48 h. The key secondary endpoints include the improvement of fractional excretion of sodium at 6 h, the total dose of furosemide, and the incidence of worsening renal function (WRF) at 48 h.Conclusions: Although the combination of diuretic treatment has recently gained more attention due to its physiologically synergistic action, its advantages may be outweighed by the substantial risk of electrolyte disturbances and severe WRF. Further, there is no consensus on the time point for early starting of add-on therapy and for the preferred diuretic combination.Trial registration: NCT04331132.Keywords
This publication has 19 references indexed in Scilit:
- Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal DysfunctionJournal of Cardiac Failure, 2016
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection FractionCirculation: Heart Failure, 2014
- Diuretic response in acute heart failure: clinical characteristics and prognostic significanceEuropean Heart Journal, 2014
- Ultrafiltration in Decompensated Heart Failure with Cardiorenal SyndromeNew England Journal of Medicine, 2012
- Early Drop in Systolic Blood Pressure and Worsening Renal Function in Acute Heart Failure: Renal Results of Pre-RELAX-AHFEuropean Journal of Heart Failure, 2011
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Tolvaptan, hyponatremia, and heart failureInternational Journal of Nephrology and Renovascular Disease, 2011
- Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart FailureJACC, 2009
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007